Literature DB >> 7533353

One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

A B Jain1, J J Fung, S Todo, J Reyes, R Selby, W Irish, H Doyle, K Abu-Elmagd, A Casavilla, B Nour.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7533353      PMCID： PMC2974336     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  12 in total

Review 1.  Lymphoproliferative disease in organ transplant recipients.

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.

Authors:  J J Fung; S Todo; A Tzakis; A Demetris; A Jain; K Abu-Elmaged; M Alessiani; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.

Authors:  T E Starzl; K Abu-Elmagd; A Tzakis; J J Fung; K A Porter; S Todo
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

Authors:  A B Jain; J J Fung; S Todo; M Alessiani; S Takaya; K Abu-Elmagd; A Tzakis; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

6.  Liver, kidney, and thoracic organ transplantation under FK 506.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

7.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

8.  One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.

Authors:  S Todo; J J Fung; A Tzakis; A J Demetris; A Jain; M Alessiani; S Takaya; R Day; R Gordon; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

9.  The question of FK 506 nephrotoxicity after liver transplantation.

Authors:  J McCauley; S Takaya; J Fung; A Tzakis; K Abu-Elmagd; A Jain; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

10.  The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors.

Authors:  S Takaya; O Bronsther; Y Iwaki; K Nakamura; K Abu-Elmagd; A Yagihashi; A J Demetris; M Kobayashi; S Todo; A G Tzakis
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939
View more
  9 in total

1.  Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient.

Authors:  Taichi Azuma; Hiroshi Narumi; Kensuke Kojima; Yuichiro Nawa; Masamichi Hara
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

2.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

3.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

4.  Gastrointestinal bleeding after liver transplantation.

Authors:  J Tabasco-Minguillán; A Jain; M Naik; K M Weber; W Irish; J J Fung; J Rakela; T E Starzl
Journal:  Transplantation       Date:  1997-01-15       Impact factor: 4.939

Review 5.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; T Cacclarelli; J McMichael; J Rakela; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

7.  A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.

Authors:  S M Pham; R L Kormos; B G Hattler; A Kawai; A C Tsamandas; A J Demetris; S Murali; F J Fricker; H C Chang; A B Jain; T E Starzl; R L Hardesty; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  1996-04       Impact factor: 5.209

8.  PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION.

Authors:  Helem Sena Ribeiro; Michelle Carvalho Oliveira; Lucilene Rezende Anastácio; Simone Vasconcelos Generoso; Agnaldo Soares Lima; Maria Isabel Correia
Journal:  Arq Bras Cir Dig       Date:  2018-06-21

9.  Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.

Authors:  Julián Alejandro Rivillas; Stephania Galindo-Coral; Francisco Arias-Mora; Juan David Lopez-Ponce de Leon; Noel Alberto Florez-Alarcón; Pastor Olaya-Rojas; Juan Esteban Gomez-Mesa
Journal:  Case Rep Cardiol       Date:  2021-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.